Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

1.3K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

671
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
671
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ecological restructuring of the nonbacterial fecal microbiome in obesity across human cohorts.

Gut microbes·2026
Same author

Aortic Repair in Landing Zone 2: From Chimney Technique to Branched Graft.

Annali italiani di chirurgia·2026
Same author

Aortic neck banding with endograft preservation for refractory type IA endoleak: The role of intraoperative duplex ultrasound.

Journal of vascular surgery cases and innovative techniques·2026
Same author

Pathophysiology and Treatment of Type 1 Diabetes in Older Adults.

Diabetes care·2026
Same author

Diagnostic and Prognostic Implications of Ultra-Low-Profile INCRAFT and Ovation Endografts: Long-Term Follow-Up in a Single-Center Experience.

Diagnostics (Basel, Switzerland)·2026
Same author

Sex-specific microbial and tryptophan signatures of depression implicate archaeal methanogens and indole-3-acetic acid only in women.

NPJ biofilms and microbiomes·2026

Related Experiment Video

Updated: Jan 11, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Glycometabolic cardiac dysfunction in HFpEF: Lessons from multi-omics studies.

Susanna Longo1, Rocco Mollace2, Viviana Casagrande3

  • 1Department of Systems Medicine and Center for Atherosclerosis, University of Rome Tor Vergata and Policlinico Tor Vergata, Rome 00133, Italy; Nutrition, Eumetabolism and Health Group, Girona Biomedical Research Institute (IDIBGI-CERCA), Girona, Spain.

Pharmacological Research
|November 14, 2025
PubMed
Summary

Heart Failure with preserved Ejection Fraction (HFpEF) involves heart tissue metabolic changes. Multi-omics and AI can uncover new biomarkers for personalized HFpEF treatments and better patient stratification.

Keywords:
Cardiac metabolismHFpEFHeart failureMetabolic inflexibilityMulti-omics

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K
Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

9.1K

Related Experiment Videos

Last Updated: Jan 11, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K
Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

9.1K

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Genomics and Proteomics

Background:

  • Heart Failure with preserved Ejection Fraction (HFpEF) is a complex syndrome characterized by myocardial biochemical alterations.
  • Loss of metabolic flexibility in heart tissue is a potential contributor to HFpEF pathogenesis and progression.
  • The heterogeneity of HFpEF complicates research and clinical management, necessitating a deeper understanding of its pathophysiology and phenotypes.

Purpose of the Study:

  • To explore the role of myocardial metabolic changes and inflexibility in the development of HFpEF.
  • To identify potential omics signatures for HFpEF using multi-omics approaches.
  • To advance personalized medicine by enabling new biomarkers for diagnosis, phenotyping, risk stratification, and targeted therapies.

Main Methods:

  • Review of current literature on myocardial metabolic changes in HFpEF.
  • Analysis of insights from multi-omics studies, including artificial intelligence and machine learning applications.
  • Focus on identifying non-traditional biomarkers beyond clinical and demographic data.

Main Results:

  • Myocardial metabolic inflexibility is implicated in HFpEF pathogenesis.
  • Multi-omics approaches offer potential for uncovering previously inaccessible insights into HFpEF metabolic changes and phenotypes.
  • The identification of an omics signature could facilitate the discovery of novel biomarkers.

Conclusions:

  • Understanding myocardial metabolic alterations is crucial for deciphering HFpEF pathophysiology.
  • Multi-omics and AI hold significant promise for characterizing HFpEF phenotypes and identifying novel biomarkers.
  • This approach can drive the development of personalized therapies and improve patient outcomes in HFpEF.